menu
    • menu
    [{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Deerfield Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Private Placement","leadProduct":"Enitociclib","moa":"PTEFb\/CDK9","graph1":"Oncology","graph2":"Phase I","graph3":"Vincerx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vincerx Pharma \/ Deerfield Management","highestDevelopmentStatusID":"6","companyTruncated":"Vincerx Pharma \/ Deerfield Management"},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Enitociclib","moa":"||PTEFb\/CDK9","graph1":"Oncology","graph2":"Phase I","graph3":"Vincerx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vincerx Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vincerx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Enitociclib","moa":"PTEFb\/CDK9","graph1":"Oncology","graph2":"Phase I","graph3":"Vincerx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vincerx Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vincerx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Enitociclib","moa":"PTEFb\/CDK9","graph1":"Oncology","graph2":"Phase I","graph3":"Vincerx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vincerx Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vincerx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Enitociclib","moa":"||PTEFb\/CDK9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vincerx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vincerx Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Vincerx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Enitociclib","moa":"PTEFb\/CDK9","graph1":"Oncology","graph2":"Phase I","graph3":"Vincerx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vincerx Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vincerx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Enitociclib","moa":"PTEFb\/CDK9","graph1":"Oncology","graph2":"Phase I","graph3":"Vincerx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vincerx Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vincerx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vincera Pharma","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Enitociclib","moa":"PTEFb\/CDK9","graph1":"Oncology","graph2":"Phase I","graph3":"Vincera Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vincera Pharma \/ Bayer AG","highestDevelopmentStatusID":"6","companyTruncated":"Vincera Pharma \/ Bayer AG"}]

    Find Clinical Drug Pipeline Developments & Deals for Enitociclib

    Menu

    Enitociclib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Vincerx Pharma

                            Germany arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            Vincerx Pharma

                            Germany arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Enitociclib,Prednisone

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Vincerx Pharma Announces Clinical Efficacy Of Enitociclib in Lymphoma Treatment

                            Details : VIP152 (enitociclib) is a selective CDK9 inhibitor in Phase 1/2 trials with venetoclax and prednisone for lymphoma, reducing oncogenes MYC and MCL1.

                            Product Name : VIP152

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 01, 2024

                            Lead Product(s) : Enitociclib,Prednisone

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Vincerx Pharma

                            Germany arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            Vincerx Pharma

                            Germany arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Enitociclib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Vincerx Pharma Presents Preclinical and Clinical Data on PTEFb/CDK9 Inhibitor VIP152 in Lymphoma at the Europe...

                            Details : Preclinical data demonstrate VIP152 as the most selective CDK9 inhibitor compared with other CDK9 inhibitors, with the most robust MYC mRNA downregulation.

                            Product Name : VIP152

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 06, 2022

                            Lead Product(s) : Enitociclib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Vincerx Pharma

                            Germany arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            Vincerx Pharma

                            Germany arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Enitociclib,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Vincerx Pharma Presents Preclinical and Preliminary Clinical Data on PTEFb/CDK9 Inhibitor VIP152 in Gynecologi...

                            Details : Findings demonstrate that VIP152 monotherapy inhibits tumor growth in an ovarian cancer xenograft model in mice. VIP152, the PTEFb/CDK9 inhibitor, used for treatment in gynecologic cancer cell lines and in patients with gynecologic malignancies.

                            Product Name : VIP152

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 04, 2022

                            Lead Product(s) : Enitociclib,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Vincerx Pharma

                            Germany arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            Vincerx Pharma

                            Germany arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Enitociclib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Vincerx Pharma Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Mee...

                            Details : VIP152, a highly selective, clinical-stage positive transcription elongation factor-beta/cyclin-dependent kinase 9 inhibitor demonstrates sensitivity in gynecologic cell lines that are cisplatin sensitive or resistant and delivers in vivo antitumor effic...

                            Product Name : VIP152

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 03, 2022

                            Lead Product(s) : Enitociclib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Vincerx Pharma

                            Germany arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            Vincerx Pharma

                            Germany arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Enitociclib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Vincerx Pharma Provides Key Strategic Update

                            Details : VIP152, a selective CDK9 inhibitor, induces complete regression of high-grade B-cell lymphoma (HGBL) models and depletion of short-lived oncogenic driver transcripts, MYC and MCL1, with a once weekly schedule.

                            Product Name : VIP152

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 06, 2022

                            Lead Product(s) : Enitociclib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Vincerx Pharma

                            Germany arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            Vincerx Pharma

                            Germany arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Enitociclib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Deerfield Management

                            Deal Size : $50.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Vincerx Pharma Announces $50 Million Private Placement

                            Details : The proceeds from the financing will support the clinical evaluation of VIP152, the Company’s potent and selective inhibitor of CDK9, in additional indications and combination regimens, as well as to advance its bioconjugation platform.

                            Product Name : VIP152

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            September 16, 2021

                            Lead Product(s) : Enitociclib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Deerfield Management

                            Deal Size : $50.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Vincerx Pharma

                            Germany arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            Vincerx Pharma

                            Germany arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Enitociclib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Vincerx Pharma Receives Orphan Drug Designation from European Commission for VIP152 for the Treatment of Diffu...

                            Details : Orphan Drug Designation is based on ongoing Phase 1b expansion of VIP152, PTEFb/CDK9 inhibitor in MYC-driven relapsed or refractory aggressive lymphomas and advanced solid tumors.

                            Product Name : VIP152

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 12, 2021

                            Lead Product(s) : Enitociclib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Vincera Pharma

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            Vincera Pharma

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Enitociclib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Bayer AG

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Vincera Pharma Announces Exclusive License Agreement with Bayer for Oncology Portfolio

                            Details : Under the terms of the license agreement, Vincera will in-license VIP152 (formerly BAY 1251152), a clinical-stage, highly selective, positive transcription elongation factor b (PTEFb)/cyclin-dependent kinase 9 (CDK9) inhibitor for the treatment of cancer...

                            Product Name : VIP152

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            August 10, 2020

                            Lead Product(s) : Enitociclib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Bayer AG

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth